

Bladder preservation with concurrent chemoradiotherapy for muscle-invasive bladder cancer: Retrospective comparison of three regimens

Supplementary File

Table S1. Early-onset adverse events in patients with muscle-invasive bladder cancer receiving radiotherapy

Treatment-related adverse events #	Overall (n=37)			RT alone (n=10)			GP-RT (n=16)			LD-Gem-RT (n=11)		
	Any grade	Grade 1/2	Grade 3 or more	Any grade	Grade 1/2	Grade 3 or more	Any grade	Grade 1/2	Grade 3 or more	Any grade	Grade 1/2	Grade 3 or more
Hematotoxicity												
Anemia	8 (22%)	5 (14%)	3 (8.1%)	1 (10%)	-	1 (10%)	5 (31%)	4 (25%)	1 (6.3%)	2 (18%)	1 (9.1%)	1 (9.1%)
Thrombocytopenia	6 (16%)	3 (8.1%)	3 (8.1%)	-	-	-	2 (13%)	1 (6.3%)	1 (6.3%)	4 (36%)	2 (18%)	2 (18%)
Neutropenia	1 (2.7%)	-	1 (2.7%)	-	-	-	6 (38%)	2 (13%)	4 (25%)	1 (9.1%)	-	1 (9.1%)
Non-hematotoxicity												
Diarrhea	11 (30%)	8 (22%)	3 (8.1%)	-	-	-	4 (25%)	3 (19%)	1 (6.3%)	7 (64%)	5 (46%)	2 (18%)
Urinary frequency	7 (19%)	7 (19%)	-	-	-	-	2 (13%)	2 (13%)	0	5 (46%)	5 (46%)	-
Fatigue	5 (14%)	4 (11%)	1 (2.7%)	1 (10%)	1 (10%)	-	3 (19%)	3 (19%)	-	1 (9.1%)	-	1 (9.1%)
Renal dysfunction	4 (11%)	4 (11%)	-	-	-	-	1 (6.3%)	1 (6.3%)	-	3 (27%)	3 (27%)	-
Hyponatremia	2 (5.4%)	1 (2.7%)	1 (2.7%)	-	-	-	1 (6.3%)	-	1 (6.3%)	1 (9.1%)	1 (9.1%)	-
Skin rash	2 (5.4%)	2 (5.4%)	-	-	-	-	1 (6.3%)	1 (6.3%)	0	1 (9.1%)	1 (9.1%)	-
Radiation cystitis	2 (5.4%)	1 (2.7%)	1 (2.7%)	1 (10%)	1 (10%)	-	1 (6.3%)	-	1 (6.3%)	-	-	-
Interstitial lung disease	1 (2.7%)	-	1 (2.7%)	-	-	-	1 (6.3%)	-	1 (6.3%) ##	-	-	-
Colitis	1 (2.7%)	-	1 (2.7%)	-	-	-	-	-	-	1 (9.1%)	-	1 (9.1%) ##
Hydronephrosis	1 (2.7%)	1 (2.7%)	-	-	-	-	-	-	-	1 (9.1%)	1 (9.1%)	-
Urinary retention	-	-	-	-	-	-	-	-	-	-	-	-
Hepatotoxicity	-	-	-	-	-	-	-	-	-	-	-	-
Urinary retention	-	-	-	-	-	-	-	-	-	-	-	-

Notes: Early-onset AEs were defined as those which occurred during the radiotherapy and the first 180 days after completion of radiotherapy. # Determined by the investigator to be drug related; ## Grade 5 adverse event.

Table S2. Late-onset adverse events in patients with muscle invasive bladder cancer receiving radiotherapy

Treatment-related adverse events #	Overall (n=37)			RT alone (n=10)			GP-RT (n=16)			LD-Gem-RT (n=11)		
	Any grade	Grade 1/2	Grade 3 or more	Any grade	Grade 1/2	Grade 3 or more	Any grade	Grade 1/2	Grade 3 or more	Any grade	Grade 1/2	Grade 3 or more
Hematotoxicity												
Anemia	1 (2.7%)	1 (2.7%)	-	-	-	-	-	-	-	1 (9.1%)	1 (9.1%)	-
Thrombocytopenia	1 (2.7%)	1 (2.7%)	-	-	-	-	-	-	-	1 (9.1%)	1 (9.1%)	-
Neutropenia	-	-	-	-	-	-	-	-	-	-	-	-
Non-hematotoxicity												
Diarrhea	-	-	-	-	-	-	-	-	-	-	-	-
Urinary frequency	3 (8.1%)	3 (8.1%)	-	1 (20%)	1 (20%)	-	-	-	-	1 (9.1%)	1 (9.1%)	-
Fatigue	1 (2.7%)	1 (2.7%)	-	-	-	-	1 (6.3%)	-	1 (6.3%)	-	-	-
Renal dysfunction	1 (2.7%)	-	1 (2.7%)	-	-	-	1 (6.3%)	-	1 (6.3%)	-	-	-
Hyponatremia	-	-	-	-	-	-	-	-	-	-	-	-
Skin rash	1 (2.7%)	1 (2.7%)	-	-	-	-	1 (6.3%)	1 (6.3%)	-	-	-	-
Radiation cystitis	6 (16%)	2 (5.4%)	4 (11%)	1 (10%)	-	1 (10%)	2 (13%)	1 (6.3%)	1 (6.3%)	3 (27%)	1 (9.1%)	2 (18%)
Interstitial lung disease	-	-	-	-	-	-	-	-	-	-	-	-
Colitis	1 (2.7%)	-	1 (2.7%)	-	-	-	1 (9.1%)	-	1 (9.1%) ##	-	-	-
Hydronephrosis	6 (16%)	1 (2.7%)	5 (14%)	1 (10%)	-	1 (10%)	3 (19%)	1 (6.3%)	2 (13%)	2 (18%)	-	2 (18%)
Urinary retention	3 (8.1%)	2 (5.4%)	1 (2.7%)	1 (10%)	-	1 (10%)	2 (13%)	2 (13%)	-	2 (18%)	2 (18%)	-
Hepatotoxicity	1 (2.7%)	-	1 (2.7%)	-	-	-	1 (6.3%)	-	1 (6.3%)	-	-	-
Urinary infection	1 (2.7%)	-	1 (2.7%)	1 (10%)	-	1 (10%) ##	-	-	-	-	-	-

Notes: Late-onset toxicities were defined as those which occurred 180 days after completion of radiotherapy or thereafter. # Determined by the investigator to be drug related; ## Grade 5 adverse event.